Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports ...

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...

Oklo: Unresolved Capital, Licensing, And Fuel Risks Potentially Signal Meltdown

Oklo is an advanced nuclear reactor developer that is centered on the creation of their Aurora reactors. Read why I rate OKLO ...

Celltrion USA: FDA approves expanded pediatric indications for YUFLYMA (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

York County to conduct smoke testing for sewer repairs

Smoke testing will be conducted in select areas of York County, VA over the next two weeks to identify areas where repairs are needed to improve sewer performance and reduce rainwater infiltration.

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...
The Manila Times

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...